Publications by authors named "Petra Vockova"

Ibrutinib revolutionized therapy for relapsed/refractory (R/R) mantle cell lymphoma (MCL). Real-world data on the outcome of unselected patients are still limited. We analyzed 77 R/R MCL patients receiving ibrutinib with at least one prior systemic anti-lymphoma therapy.

View Article and Find Full Text PDF
Article Synopsis
  • * A study analyzed 15 different PDX models from various NHL types, confirming that PDXs retained the genetic diversity of the original tumors through whole exome sequencing (WES).
  • * However, the tumor microenvironment (TME) in PDXs showed notable differences, including altered cell morphology, reduced immune cell presence, and lower blood vessel density, suggesting that while genetic profiles are maintained, the PDXs do not fully replicate the original cancer environment.
View Article and Find Full Text PDF

Despite the development of novel targeted drugs, the molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) still poses a substantial therapeutic challenge. DLBCL can be classified into at least 2 major subtypes (germinal center B cell [GCB]-like and activated B cell [ABC]-like DLBCL), each characterized by specific gene expression profiles and mutation patterns. Here we demonstrate a broad antitumor effect of dimethyl fumarate (DMF) on both DLBCL subtypes, which is mediated by the induction of ferroptosis, a form of cell death driven by the peroxidation of phospholipids.

View Article and Find Full Text PDF

Tumor oxygenation and vascularization are important parameters that determine the aggressiveness of the tumor and its resistance to cancer therapies. We introduce dual-modality ultrasound and photoacoustic imaging (US-PAI) for the direct, non-invasive real-time in vivo evaluation of oxygenation and vascularization of patient-derived xenografts (PDXs) of B-cell mantle cell lymphomas. The different optical properties of oxyhemoglobin and deoxyhemoglobin make it possible to determine oxygen saturation (sO) in tissues using PAI.

View Article and Find Full Text PDF

Platelet/endothelial cell adhesion molecule 1 (PECAM-1, CD31) is an immunoglobulin superfamily member expressed on the surface of platelets, leukocytes and endothelial cells. The role of CD31 in biology of lymphomas has not yet been systemically studied. Expression of cell surface CD31 was analyzed by flow cytometry on primary MCL cells isolated from peripheral blood, bone marrow or malignant effusions obtained from 29 newly diagnosed MCL patients.

View Article and Find Full Text PDF
Article Synopsis
  • - Mantle cell lymphoma (MCL) is a rare and challenging type of B-cell non-Hodgkin lymphoma that often resurfaces after treatment, making it a difficult condition to manage.
  • - This study developed new HPMA-based polymer nanotherapeutics that contain the chemotherapy drug cytarabine (araC), showing improved anti-lymphoma effects compared to traditional free araC in patient-derived models.
  • - The results indicated that araC co-polymers led to long-lasting tumor disappearance without any observed toxicity, suggesting they could be an effective treatment option for MCL patients in various stages of the disease.
View Article and Find Full Text PDF
Article Synopsis
  • B-cell non-Hodgkin lymphomas (B-NHL) are the most prevalent blood cancers in Western countries and often relapse after standard treatments combining chemotherapy and the antibody rituximab.
  • New treatment options are needed for patients with relapsed or refractory B-NHL, leading to the development of hybrid antibody-drug conjugates (APDC) that use mAbs targeting CD20, CD38, or CD19 combined with a polymer-drug system containing doxorubicin.
  • Tests on patient-derived lymphoma models show that targeting with the anti-CD38 antibody daratumumab significantly outperformed other therapies, suggesting a promising avenue for personalized cancer treatment using innovative APDC biomaterials.
View Article and Find Full Text PDF
Article Synopsis
  • Mantle cell lymphoma (MCL) is an aggressive B-cell cancer where BCL2 is overexpressed; the drug venetoclax targets BCL2 but resistance can occur in MCL cells.
  • Key proteins BIM and NOXA are crucial for venetoclax-induced cell death, yet they are expressed differently in cancer cell lines compared to primary cells, with NOXA being overexpressed in MCL cell lines.
  • Combining venetoclax with the MCL1 inhibitor S63845 shows promise in overcoming resistance and may provide a new treatment approach for resistant MCL patients with adverse genetic profiles.
View Article and Find Full Text PDF
Article Synopsis
  • ABC and germinal center B-cell-like diffuse large B-cell lymphoma (DLBCL) are two major subtypes with different clinical outcomes and reliance on specific oncogenic pathways.
  • A study tested novel compounds, finding that the PI3Kα/δ inhibitor AZD8835 was highly effective for ABC DLBCL, while the AKT inhibitor AZD5363 worked well in PTEN-deficient DLBCL, regardless of subtype.
  • Combining AZD8835 with the Bruton's tyrosine kinase inhibitor ibrutinib showed synergistic effects, suggesting that treatment should be personalized based on the tumor's oncogenic dependencies.
View Article and Find Full Text PDF

Tumor immunotherapy based on the use of chimeric antigen receptor modified T cells (CAR T cells) is a promising approach for the treatment of refractory hematological malignancies. However, a robust response mediated by CAR T cells is observed only in a minority of patients and the expansion and persistence of CAR T cells is mostly unpredictable.Lenalidomide (LEN) is an immunomodulatory drug currently approved for the treatment of multiple myeloma (MM) and mantle cell lymphoma, while it is clinically tested in the therapy of diffuse large B-cell lymphoma of activated B cell immunophenotype.

View Article and Find Full Text PDF

Mantle cell lymphoma (MCL) is characterized by an aggressive clinical course and inevitable development of refractory disease, stressing the need to develop alternative therapeutic strategies. To this end, we evaluated pevonedistat (MLN4924), a novel potent and selective NEDD8-activating enzyme inhibitor in a panel of MCL cell lines, primary MCL tumor cells, and 2 distinct murine models of human MCL. Pevonedistat exposure resulted in a dose-, time-, and caspase-dependent cell death in the majority of the MCL cell lines and primary tumor cells tested.

View Article and Find Full Text PDF

Purpose: To investigate the roles of BCL2, MCL1, and BCL-XL in the survival of diffuse large B-cell lymphoma (DLBCL).

Experimental Designs: Immunohistochemical analysis of 105 primary DLBCL samples, and Western blot analysis of 18 DLBCL cell lines for the expression of BCL2, MCL1, and BCL-XL. Pharmacologic targeting of BCL2, MCL1, and BCL-XL with ABT-199, homoharringtonine (HHT), and ABT-737.

View Article and Find Full Text PDF

Mantle cell lymphoma (MCL) is a chronically relapsing aggressive type of B-cell non-Hodgkin lymphoma considered incurable by currently used treatment approaches. Fludarabine is a purine analog clinically still widely used in the therapy of relapsed MCL. Molecular mechanisms of fludarabine resistance have not, however, been studied in the setting of MCL so far.

View Article and Find Full Text PDF

Background: Mantle cell lymphoma (MCL) is an aggressive type of B-cell non-Hodgkin lymphoma associated with poor prognosis. Implementation of high-dose cytarabine (araC) into induction therapy became standard-of-care for all newly diagnosed younger MCL patients. However, many patients relapse even after araC-based regimen.

View Article and Find Full Text PDF

Mantle cell lymphoma (MCL) is an aggressive type of B-cell non-Hodgkin lymphoma (NHL) associated with poor prognosis. Animal models of MCL are scarce. We established and characterized various in vivo models of metastatic human MCL by tail vein injection of either primary cells isolated from patients with MCL or established MCL cell lines (Jeko-1, Mino, Rec-1, Hbl-2, and Granta-519) into immunodeficient NOD.

View Article and Find Full Text PDF